NeoStem Inc. (NYSEMKT:NBS) Down 18.33%, Delcath Systems, Inc. (NASDAQ:DCTH) Also Down 16.55%
Northern, WI 04/30/2013 (GDPInsider) – NeoStem Inc. (NYSEMKT:NBS) is facing strong headwinds today and is trading down at 18.33%. The stock opened at $0.51 having previously closed at $0.52. Volume is 4.35 million and the stock has a trading range of $0.50 and $0.55. The decline in the stock is almost anomalous to news released by the company recently. As a biopharmaceutical company NeoStem is a world-leader and the company recently announced that one of its subsidiaries, Progenitor Cell Therapy LLC (PCT), has entered into a services agreement with Sentien Biotechnologies. The agreement will see PCT supplying services to Sentien as the latter moves towards the development of its own cell therapy product. On the face of it this is good news, however, the stock hasn’t responded in kind.
Right now NBS is moving south and the stock is trading down 18.04% on its 50-day moving average and down 20.41% on its 20-day moving average. EPS next year is tipped to drop by 18.25% and analysts have set a target price for the stock at $3.25.
Is NBS a solid investment at these levels? Get exclusive data and trends here.
Delcath Systems, Inc. (NASDAQ:DCTH) is another stock having a turbulent time in today’s trading. The stock started the day’s trading at $1.14 and is down 17.27% on trading volume of $1.13 and $1.23. Delcath Systems has been trending southwards since the beginning of April 2013 and today’s drop sees the stock down 31.25% below its 50-day simple moving average. It is also down 27.42% on its 20-day simple moving average and a sizable 61.56% off the 52-week high of $2.94.
Delcath Systems has pivoted in terms of the drug development and trial process and many are expecting big things to happen when the company goes up for FDA approval in September 2013. This prospect has not been enough, however, to allay the fears of some analysts. Many point to the on-going financing problems faced by the company and whether given these uncertainties, the company will be able to hold strong till FDA approval is granted. The stock is up just 11.88% on its 52-week low of $1.01 and has a market cap of 134.48 million.
How Should Investors Trade DCTH Now? Get exclusive insights and updates here.
WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.